Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Een grafeen verinfrarood interventiestudie van cognitieve status bij oudere volwassenen

This study was a 4-week facility-level cluster-controlled trial examining whether a graphene-based far-infrared intervention could improve cognitive status among older adults living in long-term care facilities. Five facilities were assigned to one of three study conditions: a graphene-based far-infrared intervention (GFII), a thermal-effects control (TEC) delivered using an electrically heated cap at the same nominal temperature, or a blank control condition without intervention. Participants in the GFII and TEC groups received one 40-minute session daily for 4 weeks. Cognitive outcomes were assessed at baseline, after approximately 2 and 4 weeks of intervention, and at a 4-week post-intervention follow-up. Depressive and anxiety symptoms were also assessed as exploratory outcomes, although they were not the primary focus of the study. The study aimed to examine whether GFII could improve cognitive status beyond the effects of thermal stimulation alone or no intervention.

Studie Overzicht

Studietype

Ingrijpend

Inschrijving (Werkelijk)

168

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

    • Beijing Municipality
      • Beijing, Beijing Municipality, China, 100101
        • Institute of Psychology, Chinese Academy of Sciences

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

55 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Aged 55 years or older
  • Residing in one of the participating long-term care facilities
  • Able to communicate in daily life
  • Willing to participate in the assigned study procedures and repeated assessments

Exclusion Criteria:

  • Reporting no subjective cognitive decline on any item of the subjective cognitive decline questionnaire
  • Having a medical condition that precluded localized head heating

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Niet-gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Enkel

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Graphene far infrared intervention group

Participants received a graphene-based far-infrared intervention (GFII) using a wearable cap set to a nominal temperature of 40°C. Trained caregivers assisted participants with one 40-minute session daily for 4 weeks of active intervention. Participants could sit, lie down, or undertake routine activities during each session.

The GFII was delivered using a custom wearable cap comprising a flexible cap body with graphene-coated elements, a temperature controller, and an external power adapter. The cap covered the frontal, temporal, and occipital scalp regions and emitted far-infrared radiation primarily within the 4-14 μm range. The device was operated at a nominal temperature of 40°C. Participants received one 40-minute session daily for 4 weeks of active intervention under the assistance and supervision of trained caregivers.

Andere namen:
  • GFII
Actieve vergelijker: Thermal-Effects Control Group

Participants received conventional electrical heating using a commercially available heated cap set to the same nominal temperature of 40°C. The intervention followed the same schedule, 40-minute session duration, and caregiver-assistance procedures as the GFII condition.

The thermal-effects control was delivered using a commercially available electrically heated cap without graphene-based far-infrared-emitting elements. The cap was operated at the same nominal temperature of 40°C and followed the same intervention schedule, 40-minute session duration, and caregiver-assistance procedures as the GFII condition.

Andere namen:
  • TEC
Geen tussenkomst: Blank Control Group

Participants received no cap-based intervention and continued their usual daily routines during the study period.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Subjective Cognitive Decline (SCD) Score
Tijdsspanne: Baseline (T1), after approximately 2 weeks of active intervention (T2), after completion of 4 weeks of active intervention (T3), and approximately 4 weeks after T3 (T4)

Subjective cognitive decline was assessed using a 10-item multidomain, example-assisted questionnaire. Participants rated perceived cognitive change relative to 1-2 years earlier on a three-point scale ranging from 1 (no decline) to 3 (obvious decline). Total scores range from 10 to 30, with higher scores indicating greater subjective cognitive decline.

Baseline (T1), after approximately 2 weeks of active intervention (T2), after completion of 4 weeks of active intervention (T3), and approximately 4 weeks after T3 (T4)
Mini-Montreal Cognitive Assessment (Mini-MoCA) Score
Tijdsspanne: Baseline (T1), after approximately 2 weeks of active intervention (T2), after completion of 4 weeks of active intervention (T3), and approximately 4 weeks after T3 (T4)

Objective cognitive performance was assessed using the Mini-Montreal Cognitive Assessment (Mini-MoCA), which evaluates visuospatial and executive function, attention, language, abstraction, delayed recall, and orientation. Raw scores range from 0 to 17. Following the scoring instructions, one point was added for participants with fewer than 12 years of education, yielding an education-adjusted score range of 0 to 18. Higher scores indicate better cognitive performance. Scores were analyzed continuously and were not used for clinical diagnosis.

Baseline (T1), after approximately 2 weeks of active intervention (T2), after completion of 4 weeks of active intervention (T3), and approximately 4 weeks after T3 (T4)

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Patient Health Questionnaire-9 (PHQ-9) Score
Tijdsspanne: Baseline (T1), after approximately 2 weeks of active intervention (T2), after completion of 4 weeks of active intervention (T3), and approximately 4 weeks after T3 (T4)

Depressive symptoms were assessed using the nine-item Patient Health Questionnaire (PHQ-9). Each item is scored from 0 (not at all) to 3 (nearly every day) based on the frequency of depressive symptoms during the preceding 2 weeks. Total scores range from 0 to 27, with higher scores indicating more severe depressive symptoms. Scores of 10 or higher indicate clinically relevant depressive symptoms.

Baseline (T1), after approximately 2 weeks of active intervention (T2), after completion of 4 weeks of active intervention (T3), and approximately 4 weeks after T3 (T4)
Generalized Anxiety Disorder-7 (GAD-7) Score
Tijdsspanne: Baseline (T1), after approximately 2 weeks of active intervention (T2), after completion of 4 weeks of active intervention (T3), and approximately 4 weeks after T3 (T4)

Anxiety symptoms were assessed using the Chinese version of the seven-item Generalized Anxiety Disorder scale (GAD-7). Each item is scored from 0 (not at all) to 3 (nearly every day) based on the frequency of anxiety symptoms during the preceding 2 weeks. Total scores range from 0 to 21, with higher scores indicating more severe anxiety symptoms. Scores of 10 or higher indicate clinically relevant anxiety symptoms.

Baseline (T1), after approximately 2 weeks of active intervention (T2), after completion of 4 weeks of active intervention (T3), and approximately 4 weeks after T3 (T4)

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

1 maart 2025

Primaire voltooiing (Werkelijk)

11 mei 2025

Studie voltooiing (Werkelijk)

11 mei 2025

Studieregistratiedata

Eerst ingediend

19 februari 2025

Eerst ingediend dat voldeed aan de QC-criteria

19 februari 2025

Eerst geplaatst (Werkelijk)

25 februari 2025

Updates van studierecords

Laatste update geplaatst (Werkelijk)

3 november 2026

Laatste update ingediend die voldeed aan QC-criteria

30 oktober 2026

Laatst geverifieerd

1 oktober 2026

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • 2023YFC3605304-1
  • 2023YFC3605304 (Ander subsidie-/financieringsnummer: National Key Research and Development projects)

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

Beschrijving IPD-plan

De-identified participant-level clinical outcome data underlying the findings reported in the publication will be available from the corresponding author upon reasonable request. Access to biomarker data will be considered separately, subject to ethical approval, data-use agreements, and applicable privacy requirements. Potentially identifying information will be withheld or minimized to protect participant privacy.

IPD-tijdsbestek voor delen

Beginning at publication and continuing for 3 years thereafter.

IPD-toegangscriteria voor delen

Data will be considered for sharing with qualified researchers for noncommercial research purposes, including verification of the reported findings. Requests must include an appropriate research proposal and will be subject to applicable ethical and institutional requirements and a data-use agreement. Requests should be directed to the corresponding author.

IPD delen Ondersteunend informatietype

  • LEERPROTOCOOL
  • SAP

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren